(HealthDay)—Two new studies could pave the way to major changes in how severe cases of hemophilia are treated. Both studies were published in the May 26 issue of the New England Journal of Medicine.
May 26, 2016
0
14
Despite significant advances in hemophilia therapies and increased access to integrated treatment centers over the last half century, men with severe forms of this disease still experience physical limitations and disability, ...
Mar 16, 2016
0
8
Sufferers of hemophilia live in a perpetual state of stress and anxiety: their joints wear down prematurely and they have bleeding episodes that feel like they will never end. Their bodies lack the ability to make the clotting ...
Jul 24, 2015
0
80
Children with hemophilia A require three to four infusions each week to prevent bleeding episodes, chronic pain and joint damage. The effect on quality of life can be significant, due to time and discomfort associated with ...
Apr 24, 2015
0
349
Alnylam Pharmaceuticals, Inc. announced today the publication in Nature Medicine of pre-clinical results with ALN-AT3, an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare ...
Apr 14, 2015
0
9
Using gene therapy to produce a mutant human protein with unusually high blood-clotting power, scientists have successfully treated dogs with the bleeding disorder hemophilia, without triggering an unwanted immune response. ...
Mar 12, 2015
0
13
(HealthDay)—Obizur (antihemophilic factor recombinant) has been approved to treat a rare, non-inherited form of hemophilia in adults.
Oct 24, 2014
0
0
The drug Alprolix has been approved by the U.S. Food and Drug Administration as the first long-acting hemophilia B clotting agent, the FDA said in a news release.
Mar 31, 2014
0
0
Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and ...
Dec 11, 2013
0
0
Prothrombin complex concentrates (PCCs) are faster and more effective than fresh frozen plasma at reversing hemorrhage caused by the anti-coagulant warfarin, despite plasma being the most commonly used therapy. A literature ...
Aug 2, 2013
0
0
